Biomea Fusion announced three icovamenib abstracts for presentation at the ADA 2026, showcasing its impact on diabetes management.
Quiver AI Summary
Biomea Fusion, Inc. announced that three abstracts on icovamenib, its investigational oral menin inhibitor, have been selected for late-breaking poster presentations at the American Diabetes Association's 86th Scientific Sessions from June 5-8, 2026, in New Orleans. The presentations will showcase data supporting icovamenib's efficacy in enhancing beta cell function for both type 1 and type 2 diabetes, emphasizing its potential to improve metabolic health. Specific presentations include a subgroup analysis on glycemic improvements in type 2 diabetes patients on GLP-1 therapy, improvements in insulin secretion for type 1 diabetes, and the activation of mechanisms that support metabolic health. Icovamenib is currently in Phase 2 clinical development and aims to provide a novel, short-course therapy for diabetes management. Biomea is committed to developing transformative treatments targeting diabetes and obesity, addressing the global health challenge of metabolic disorders.
Potential Positives
- Three abstracts related to icovamenib have been selected for late-breaking presentations at a major conference, showcasing the company’s innovative research and potential advancements in diabetes treatment.
- The findings highlight icovamenib's ability to improve beta cell function and metabolic health, indicating a significant therapeutic potential that may attract interest from investors and the medical community.
- Presenting at the American Diabetes Association's Scientific Sessions enhances Biomea's visibility and credibility in the diabetes and obesity treatment landscape, potentially leading to increased partnerships and funding opportunities.
Potential Negatives
- The press release focuses heavily on the potential benefits of icovamenib, but provides no information on any existing safety or efficacy concerns that may arise during the ongoing clinical trials.
- It does not mention any financial performance metrics or projections, which could raise concerns about the company's financial stability and investor confidence.
- The reliance on a single investigational drug, icovamenib, for the company's pipeline may pose a risk if the drug fails to meet regulatory approval or market expectations.
FAQ
What is icovamenib and its role in diabetes treatment?
Icovamenib is an investigational oral menin inhibitor targeting beta cell dysfunction in diabetes, currently in Phase 2 clinical development.
When will Biomea present icovamenib data at the ADA conference?
Biomea will present three icovamenib abstracts at the ADA 86th Scientific Sessions from June 5-8, 2026, in New Orleans.
Who will present the icovamenib research at the conference?
Juan Pablo Frías, M.D. and Mini Balakrishnan, Ph.D. will present the icovamenib research during the late-breaking poster sessions.
What are the main findings related to icovamenib in the studies?
The studies highlight icovamenib's potential to improve beta cell function and support metabolic health in both type 1 and type 2 diabetes.
Where can I find the presentation materials after the ADA conference?
Presentation materials will be available on the Diabetes® journal website and in the Investors & Media section of Biomea's website.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BMEA Insider Trading Activity
$BMEA insiders have traded $BMEA stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BMEA stock by insiders over the last 6 months:
- MICHAEL J.M. HITCHCOCK (Interim CEO) purchased 100,000 shares for an estimated $99,180
- RAINER M ERDTMANN (See Remarks) has made 2 purchases buying 50,000 shares for an estimated $54,552 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
$BMEA Hedge Fund Activity
We have seen 25 institutional investors add shares of $BMEA stock to their portfolio, and 36 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CORMORANT ASSET MANAGEMENT, LP removed 3,570,872 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $4,427,881
- HEIGHTS CAPITAL MANAGEMENT, INC removed 1,437,646 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $1,782,681
- FMR LLC added 1,196,507 shares (+15.7%) to their portfolio in Q4 2025, for an estimated $1,483,668
- MARSHALL WACE, LLP added 865,618 shares (+293.7%) to their portfolio in Q4 2025, for an estimated $1,073,366
- VANGUARD GROUP INC added 797,975 shares (+36.8%) to their portfolio in Q4 2025, for an estimated $989,489
- MARINER, LLC added 346,702 shares (+145.1%) to their portfolio in Q4 2025, for an estimated $429,910
- BLACKROCK, INC. removed 269,490 shares (-29.9%) from their portfolio in Q4 2025, for an estimated $334,167
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
$BMEA Analyst Ratings
Wall Street analysts have issued reports on $BMEA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 11/10/2025
To track analyst ratings and price targets for $BMEA, check out Quiver Quantitative's $BMEA forecast page.
$BMEA Price Targets
Multiple analysts have issued price targets for $BMEA recently. We have seen 3 analysts offer price targets for $BMEA in the last 6 months, with a median target of $9.0.
Here are some recent targets:
- Jonathan Wolleben from Citizens set a target price of $9.0 on 05/05/2026
- Jason Kolbert from D. Boral Capital set a target price of $12.0 on 04/28/2026
- Yigal Nochomovitz from Citigroup set a target price of $7.0 on 03/27/2026
Full Release
SAN CARLOS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that three icovamenib abstracts have been selected for late-breaking poster presentations at the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5–8, 2026 in New Orleans. The presentations include data from icovamenib, the Company’s investigational oral menin inhibitor, across both type 1 and type 2 diabetes, highlighting its potential to improve beta cell function and support metabolic health.
Presentation Details
Title:
Glycemic Improvements with Icovamenib in T2D on Background GLP-1 Therapy: COVALENT-111 Subgroup Analysis
Session:
Late-Breaking Poster Session 2857-LB
Presenter:
Juan Pablo Frías, M.D.
Date/Time:
June 7, 2026, at 12:30 pm – 1:30 pm CT
Title:
Icovamenib, a Menin Inhibitor, Improves Endogenous Insulin Secretion in Type 1 Diabetes: Results from the COVALENT-112 Study
Session:
Late-Breaking Poster Session 2858-LB
Presenter:
Juan Pablo Frías, M.D.
Date
: June 7, 2026, at 12:30 pm – 1:30 pm CT
Title:
Menin Inhibitor Icovamenib Activates Mechanisms That Support Metabolic Health
Session:
Late-Breaking Poster Session 2871-LB
Presenter:
Mini Balakrishnan, Ph.D.
Date/Time:
June 7, 2026, at 12:30 pm – 1:30 pm CT
All presentations will be available following the lifting of the embargo on Friday, June 5, 2026, at 6:30 PM CT. At that time, materials will be published on the Diabetes ® journal website and in the Investors & Media section of Biomea’s website.
About Icovamenib
Icovamenib is an orally administered investigational small molecule currently in Phase 2 clinical development for the treatment of diabetes. Icovamenib targets menin, a transcriptional regulator implicated in beta cell dysfunction, and has been shown in preclinical and clinical studies to induce transient reductions in menin protein levels in pancreatic islets, thereby modulating pathways associated with insulin secretion and glycemic control. Through this mechanism, icovamenib has the potential to restore beta cell mass and function and improve endogenous insulin production. As a potential short-course therapy, icovamenib could represent a novel treatment approach for patients with diabetes, particularly those who have not achieved adequate control with standard-of-care therapies.
About Biomea Fusion
Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.
Visit us at www.biomeafusion.com and follow us on LinkedIn , X and Facebook .
Contact:
Meichiel Jennifer Weiss
Sr. Director of Investor Relations and Corporate Development
[email protected]
